Methylene bis(4-cyclohexylisocyanate) (also known as MDI or H12MDI) is a diisocyanate used in the production of polyurethane foams, coatings, and elastomers. It is synthesized through the reaction of cyclohexylamine with phosgene. MDI is a highly reactive compound, and its polymerization can produce rigid or flexible foams with different properties. MDI-based polymers are used in a wide range of applications, including insulation, furniture, automotive parts, and construction materials. The high reactivity of MDI can pose a health hazard, as it can cause respiratory irritation and allergic reactions. Therefore, its handling requires appropriate safety precautions.'
methylene bis(4-cyclohexylisocyanate): used in manufacture of polyurethane foam; RN given refers to cpd without isomeric designation
dicyclohexylmethane-4,4'-diisocyanate : A diisocyanate consisting of dicyclohexylmethane with two isocyanate groups at the 4- and 4'-positions.
ID Source | ID |
---|---|
PubMed CID | 21202 |
CHEMBL ID | 1878565 |
CHEBI ID | 53216 |
SCHEMBL ID | 22543 |
SCHEMBL ID | 5902920 |
SCHEMBL ID | 5903114 |
SCHEMBL ID | 8733246 |
SCHEMBL ID | 6318341 |
SCHEMBL ID | 10507329 |
SCHEMBL ID | 19751835 |
SCHEMBL ID | 22958492 |
SCHEMBL ID | 24783191 |
MeSH ID | M0061489 |
Synonym |
---|
4,4'-methylenedi(cyclohexyl isocyanate) |
cyclohexane, 1,1'-methylenebis[4-isocyanato- |
isocyanic acid, methylenedi-4,1-cyclohexylene ester |
methylene bis-(4-cyclohexylisocyanate) |
brn 2217800 |
hylene w |
cp 99173 |
dicyclohexylmethane-4,4'-diisocyanate |
dicyclohexylmethane 4,4'-diisocyanate |
cyclohexane, 1,1'-methylenebis(4-isocyanato- |
1,1-methylenebis(4-isocyanatocyclohexane) [diisocyanates] |
nacconate h 12 |
methylene bis(4-cyclohexylisocyanate) |
einecs 225-863-2 |
4,4'-methylenedicyclohexyl diisocyanate |
methylenebis(4-cyclohexylisocyanate) |
4,4'-diisocyanatodicyclohexylmethane |
hsdb 7189 |
bis(4-isocyanatocyclohexyl)methane |
5124-30-1 |
NCGC00164262-01 |
1,1'-methylenebis(4-isocyanatocyclohexane) |
dicyclohexylmethane-4,4'-di-isocyanate |
CHEBI:53216 , |
1-isocyanato-4-[(4-isocyanatocyclohexyl)methyl]cyclohexane |
D2380 |
4,4'-methylenebis(cyclohexyl isocyanate) |
AKOS000120188 |
z717id22kx , |
cyclohexane, 1,1'-methylenebis(4-isocyanato-, (trans,trans)- |
unii-z717id22kx |
4,4'-diisocyanatodicyclohexylmethane, trans,trans- |
13622-90-7 |
28605-81-4 |
cyclohexane, 1,1'-methylenebis(isocyanato- |
NCGC00255393-01 |
cas-5124-30-1 |
tox21_301473 |
dtxsid3027588 , |
dtxcid307588 |
1,1-methylene bis(4-isocyanatocyclohexane) |
ec 225-863-2 |
4ct385m7k2 , |
unii-4ct385m7k2 |
1,1-methylenebis(4-isocyanatocyclohexane) |
FT-0635549 |
EPITOPE ID:113239 |
cyclohexane, 1,1'-methylenebis[4-isocyanato-, (trans,trans)- |
isocyanic acid, methylenedi-4,1-cyclohexylene ester, trans,trans- |
trans,trans-4,4'-diisocyanatodicyclohexylmethane |
trans-trans-methylenebis(4-cyclohexylisocyanate) |
4,4'-diisocyanatodicyclohexylmethane, cis,cis- |
p815vnf99i , |
4,4'-diisocyanatodicyclohexylmethane, cis,trans- |
6y80aja84r , |
cis,cis-4,4'-diisocyanatodicyclohexylmethane |
unii-6y80aja84r |
isocyanic acid, methylenedi-4,1-cyclohexylene ester, cis,cis- |
18937-00-3 |
cis-cis-methylene bis(4-cyclohexylisocyanate) |
cis,trans-4,4'-diisocyanatodicyclohexylmethane |
cyclohexane, 1,1'-methylenebis(4-isocyanato-, (cis(cis))- |
isocyanic acid, methylenedi-4,1-cyclohexylene ester, cis,trans- |
unii-p815vnf99i |
cyclohexane, 1,1'-methylenebis(4-isocyanato-, (cis(trans))- |
17901-48-3 |
cis-trans-methylene bis(4-cyclohexylisocyanate) |
SCHEMBL22543 |
SCHEMBL5902920 |
SCHEMBL5903114 |
4,4'-methylenebis-(cyclohexyl isocyanate) |
KORSJDCBLAPZEQ-UHFFFAOYSA-N |
4,4'-diisocyanato dicyclohexylmethane |
methylene-bis-(4-cyclohexyl isocyanate) |
SCHEMBL8733246 |
SCHEMBL6318341 |
CHEMBL1878565 |
methylene-bis(4-cyclohexylisocyanate) |
SCHEMBL10507329 |
F2191-0303 |
dicyclohexylmethane-4,4'-diiso cyanate |
mfcd00015405 |
hmdi, analytical standard |
(trans,trans)-1,1'-methylenebis[4-isocyanatocyclohexane] |
DTXSID30891145 |
dicyclohexyl-methane-4,4'-diisocyanate |
SCHEMBL19751835 |
Q1562648 |
Q27295091 |
Q27286344 |
Q27265708 |
BS-42301 |
SCHEMBL22958492 |
156515-75-2 |
F87466 |
SCHEMBL24783191 |
Excerpt | Relevance | Reference |
---|---|---|
" In mice, as well as in guinea pigs, a dose-response relationship was apparent between the sensitizing dose and both severity of response and number of animals responding." | ( Use of dose-response data to compare the skin sensitizing abilities of dicyclohexylmethane-4,4'-diisocyanate and picryl chloride in two animal species. Karol, MH; Stadler, JC, 1985) | 0.27 |
Role | Description |
---|---|
allergen | A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
diisocyanate | An isocyanate compound containing two isocyanate functional groups. Manufactured for reaction with polyols in the production of polyurethanes. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.6113 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 43.2771 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 50.1187 | 0.0002 | 21.2231 | 8,912.5098 | AID588515 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 48.9662 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 23.3186 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 54.4827 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 48.9662 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0794 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 8 (29.63) | 18.7374 |
1990's | 4 (14.81) | 18.2507 |
2000's | 7 (25.93) | 29.6817 |
2010's | 8 (29.63) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.69) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (3.57%) | 6.00% |
Case Studies | 3 (10.71%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 24 (85.71%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |